首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >DNA repair polymorphisms influence the risk of second neoplasm after treatment of childhood acute lymphoblastic leukemia
【24h】

DNA repair polymorphisms influence the risk of second neoplasm after treatment of childhood acute lymphoblastic leukemia

机译:DNA修复多态性影响儿童急性淋巴细胞白血病治疗后第二肿瘤的风险

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Purpose Patients treated for childhood acute lympho-blastic leukemia (ALL) are considered to be at increased risk of developing second neoplasm. The aim of our study was to identify DNA repair polymorphisms contributing to the risk of second neoplasm in clinically well-characterized Slovenian patients treated for childhood ALL. Methods Pediatric patients diagnosed with ALL between 1971 and 2001 were included in the study. According to the identified clinical risk factors for second neoplasm, a matched set of cases with second neoplasm and controls was selected and genotyped for 11 DNA repair polymorphisms. Results Among 359 pediatric patients with ALL, 20 second neoplasms were observed. The dose of radiotherapy (P = 0.011), administration of epipodophyllotoxins (P = 0.006), and the dose of anthracyclines (P < 0.001) showed a significant association with the risk of second neoplasm. Among genetic factors, we observed a significant association of NBN 1197G allele with increased risk of second neoplasms (RR = 4.36; 95 % CI: 1.19-15.98; P = 0.026), while the risk was decreased in carriers of XRCC3-316G allele compared with patients with wild-type genotype (RR = 0.20; 95 % CI: 0.04-0.99; P = 0.049). Conclusions Our results suggest an important role of NBN 1197A>G and XRCC3-316A>G polymorphisms in the development of second neoplasm in patients treated for childhood ALL.
机译:目的治疗儿童急性淋巴细胞白血病(ALL)的患者被认为患第二肿瘤的风险增加。我们研究的目的是鉴定治疗儿童ALL的临床特征明确的斯洛文尼亚患者的DNA修复多态性,其有助于第二发肿瘤的风险。方法将1971年至2001年间诊断为ALL的小儿患者纳入研究。根据确定的第二肿瘤的临床危险因素,选择一组具有第二肿瘤和对照的匹配病例,并进行基因分型以检测11种DNA修复多态性。结果359例小儿ALL患者中,观察到20例次生肿瘤。放疗剂量(P = 0.011),表鬼臼毒素的使用量(P = 0.006)和蒽环类药物的剂量(P <0.001)与第二肿瘤的发生风险显着相关。在遗传因素中,我们观察到NBN 1197G等位基因与第二肿瘤风险增加显着相关(RR = 4.36; 95%CI:1.19-15.98; P = 0.026),而与XRCC3-316G等位基因携带者相比,风险降低具有野生型基因型的患者(RR = 0.20; 95%CI:0.04-0.99; P = 0.049)。结论我们的结果表明NBN 1197A> G和XRCC3-316A> G多态性在儿童ALL治疗的第二肿瘤的发生中具有重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号